Transduced B cells: B is for 'beneficial'!

David W. Scott*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

5 Scopus citations


B cells have been used as tolerogenic APCs for nearly two decades. However, the ability to transduce B cells for use in gene therapy has been hampered by the low efficiency of transduction of resting B cells. This has been partially overcome by mitogenic activation of these cells, a factor that is not without risks as activated B cells may become pathogenic. In this issue of the European Journal of Immunology, this challenge is met by achieving high-efficiency transduction of resting murine B cells with a lentiviral vector. Furthermore, the application of this protocol to generate MOG-expressing B cells and successfully prevent EAE, as described in this issue, is an important step forward in B-cell therapy.

Original languageEnglish
Pages (from-to)1528-1530
Number of pages3
JournalEuropean Journal of Immunology
Issue number6
StatePublished - Jun 2011
Externally publishedYes


  • B cells
  • Gene therapy
  • Lentivirus
  • Tolerance


Dive into the research topics of 'Transduced B cells: B is for 'beneficial'!'. Together they form a unique fingerprint.

Cite this